Satisfaction with antipsychotics as a medication: the role of therapeutic alliance and patient-perceived participation in decision making in patients with schizophrenia spectrum disorder

References

• Abdel-Baki A, Ouellet-Plamondon C, Malla A. 2012. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord. 138:S3–S14.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders: DSM-5. 2nd ed. Arlington (VA): American Psychiatric Association; p. 947.
   Google Scholar
• Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. 2004. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2(1):12.
   PubMedGoogle Scholar
• Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. 2011. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res. 130(1–3):176–181.
   PubMed Web of Science ®Google Scholar
• Bordin ES. 1979. The generalizability of the psychoanalytic concept of the working alliance. Psychother Theory, Res Pract. 16(3):252–260.
   Google Scholar
• Caseiro O, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Pelayo-Terán JM, Tabares-Seisdedos R, Ortiz-García de la Foz V, Vázquez-Barquero JL, Crespo-Facorro B. 2012. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 46(8):1099–1105.
   PubMed Web of Science ®Google Scholar
• Chue P. 2006. The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol. 20(6):38–56.
   PubMedGoogle Scholar
• Coldham EL, Addington J, Addington D. 2002. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 106(4):286–290.
   PubMed Web of Science ®Google Scholar
• Corbella S, Botella L, María Gómez A, Herrero O, Pacheco M. 2011. Características psicométricas de la versión española del Working Alliance Inventory-Short (WAI-S) [Psychometric properties of Spanish version of the Working Alliance Inventory-Short (WAI-S)]. An Psicol. 27:298–301.
   Google Scholar
• Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M, Kinnersley P, Houston H, Russell I. 2003. The development of COMRADE—a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. Patient Educ Couns. 50(3):311–322.
   PubMed Web of Science ®Google Scholar
• Edwards A, Elwyn G, Mulley A. 2002. Explaining risks: turning numerical data into meaningful pictures. BMJ. 324(7341):827–830.
   PubMed Web of Science ®Google Scholar
• Frank AF, Gunderson JG. 1990. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry. 47(3):228–236.
   PubMed Web of Science ®Google Scholar
• Freeman DH. 1987. Applied categorical data analysis. New York (NY): Marcel Dekker Inc.; p. 318.
   Google Scholar
• Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, et al. 2008. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 32(3):755–760.
   PubMed Web of Science ®Google Scholar
• Gasquet I, Tcherny-Lessenot S, Lépine JP, Falissard B. 2006. Patient satisfaction with psychotropic drugs: sensitivity to change and relationship to clinical status, quality-of-life, compliance and effectiveness of treatment. Results from a nation-wide 6-month prospective study. Eur Psychiatr. 21(8):531–538.
   PubMed Web of Science ®Google Scholar
• Gerber GJ, Prince PN. 1999. Measuring client satisfaction with assertive community treatment. Psychiatr Serv. 50(4):546–550.
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Greenspan A, Rupnow MF, Kosik-Gonzalez C, Bossie CA, Zhu Y, Kalali AH, Awad AG. 2006. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 6(1):45.
   PubMedGoogle Scholar
• Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E. 2007. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord. 9(1–2):45–52.
   PubMed Web of Science ®Google Scholar
• Hamann J, Cohen R, Leucht S, Busch R, Kissling W. 2005. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry. 162(12):2382–2384.
   PubMed Web of Science ®Google Scholar
• Hamann J, Cohen R, Leucht S, Busch R, Kissling W. 2007. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry. 68(7):992–997.
   PubMed Web of Science ®Google Scholar
• Hellewell JSE. 2002. Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs. 16(7):457–471.
   PubMed Web of Science ®Google Scholar
• Hogan TP, Awad AG, Eastwood R. 1983. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 13(1):177–183.
   PubMed Web of Science ®Google Scholar
• Horvath AO, Greenberg LS. 1986. The development of the Working Alliance Inventory. In: Greenberg LS, Pinsof WM, editors. Guilford clinical psychology and psychotherapy series. The psychotherapeutic process: a research handbook. New York (NY): Guilford Press; p. 529–556.
   Google Scholar
• Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. 2006. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 63(10):1079–1087.
   PubMed Web of Science ®Google Scholar
• Juckel G, de Bartolomeis A, Gorwood P, Mosolov S, Pani L, Rossi A, Sanjuan J. 2014. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatr Dis Treat. 10:1867–1878.
   PubMed Web of Science ®Google Scholar
• Kalali A. 1999a. Evaluating patient satisfaction: a practical approach. Clear Perspect. 2(3):18–21.
   Google Scholar
• Kalali A. 1999b. Patient satisfaction with, and acceptability of, atypical antipsychotics. Curr Med Res Opin. 15(2):135–137.
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. 2013. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 12(3):216–226.
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 63(10):892–909.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, et al. 2013. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 379(9831):2063–2071.
   PubMed Web of Science ®Google Scholar
• Li Q, Xiang Y-T, Su Y-A, Shu L, Yu X, Chiu HF, Correll CU, Ungvari GS, Lai KY, Ma C, et al. 2015. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China. Aust N Z J Psychiatry. 49(2):129–136.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Bouhours P, Moreau-Mallet V. 2008. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale. 34(2):170–178.
   PubMed Web of Science ®Google Scholar
• Lloyd K, Latif MA, Simpson S, Shrestha KL. 2010. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol Clin Exp. 25(3):243–252.
   PubMed Web of Science ®Google Scholar
• Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R. 2007. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. 40(6):257–263.
   PubMed Web of Science ®Google Scholar
• McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, Rössler W, Salize HJ, Svensson B, Torres-Gonzalez F, van den Brink R, et al. 2012. The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One. 7(4):e36080.
   PubMed Web of Science ®Google Scholar
• Naber D. 1995. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 10(3):133–138.
   PubMedGoogle Scholar
• Nordon C, Rouillon F, Barry C, Gasquet I, Falissard B. 2012. Determinants of treatment satisfaction of schizophrenia patients: results from the ESPASS study. Schizophr Res. 139(1–3):211–217.
   PubMed Web of Science ®Google Scholar
• Nosé M, Barbui C, Tansella M. 2003. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 33(7):1149–1160.
   PubMed Web of Science ®Google Scholar
• Pérez-Revuelta J, Villagrán-Moreno JM, Moreno-Sánchez L, Pascual-Paño JM, González-Saiz F. 2018. Patient perceived participation in decision making on their antipsychotic treatment: evidence of validity and reliability of the COMRADE scale in a sample of schizophrenia spectrum disorders. Patient Educ Couns. 101(8):1477–1482.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Bromet EJ, Davidson M. 2001. Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophr Bull. 27(4):597–600.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Lasalvia A, Bisoffi G, Thornicroft G, Vàzquez-Barquero JL, Becker T, Knapp M, Knudsen HC, Schene A, Tansella M. 2003. Satisfaction with mental health services among people with schizophrenia in five European sites: results from the EPSILON study. Schizophr Bull. 29(2):229–245.
   PubMed Web of Science ®Google Scholar
• Sendt KV, Tracy DK, Bhattacharyya S. 2015. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 225(1–2):14–30.
   PubMed Web of Science ®Google Scholar
• Sweileh WM, Ihbesheh MS, Jarar IS, Sawalha AS, Abu Taha AS, Zyoud SH, Morisky DE. 2012. Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia. Curr Clin Pharmacol. 7(1):49–55.
   PubMedGoogle Scholar
• Taira M, Hashimoto T, Takamatsu T, Maeda K. 2006. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects. Prog Neuro-Psychopharmacology Biol Psychiatry. 30(6):1139–1142.
   PubMed Web of Science ®Google Scholar
• Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, Vazquez-Barquero JL. 2004. The personal impact of schizophrenia in Europe. Schizophr Res. 69(2–3):125–132.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JPA, Volavka J, Haukka J. 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 333(7561):224–227.
   PubMed Web of Science ®Google Scholar
• Tracey TJ, Kokotovic AM. 1989. Factor structure of the Working Alliance Inventory. Psychol Assess A J Consult Clin Psychol. 1(3):207–210.
   Google Scholar
• Trujols J, Iraurgi I, Siñol N, Portella MJ, Pérez V, Pérez De Los Cobos J. 2012. Satisfaction with methadone as a medication: psychometric properties of the Spanish version of the Treatment Satisfaction Questionnaire for medication. J Clin Psychopharmacol. 32(1):69–74.
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Awad AG. 2002. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 56(1–2):37–46.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Shibata I, Kato T. 2004. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry Clin Neurosci. 58(3):268–273.
   PubMed Web of Science ®Google Scholar
• Widschwendter CG, Kemmler G, Rettenbacher MA, Yalcin-Siedentopf N, Hofer A. 2018. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. BMC Psychiatry. 18(1):212.
   PubMedGoogle Scholar